0
Letters |

Long-term Use of Aspirin and Risk of Colorectal CancerLong-term Use of Aspirin and Risk of Colorectal Cancer

JAMA. 2005;294(24):3090-3091. doi:10.1001/jama.294.24.3090-b
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

LONG-TERM USE OF ASPIRIN AND RISK OF COLORECTAL CANCER

To the Editor: In their study on aspirin, nonsteroidal anti-inflammatory drugs, and the risk of colorectal cancer, Dr Chan and colleagues1 conclude that regular, long-term aspirin use reduces risk of colorectal cancer. Although the study shows that long-term users of aspirin have a lower incidence of colorectal cancer, aspirin itself may not be the cause of this observation. The situation may be analogous to earlier results of the Nurses' Health Study,2 in which the apparent reduced cardiac and mortality risks from estrogen use may have been artifacts of confounding or selection bias, based on results of a subsequent randomized controlled trial.3

In the study by Chan et al, there was a greater percentage of nonwhite participants among the aspirin nonusers compared with the users, an important difference. It is not clear if the relative risks were adjusted for race, but when there are measured confounders there also are likely to be unmeasured confounders. This may have been the case with the estrogen cohort studies, in which differences in lifetime socioeconomic status may have contributed both to differences in cardiovascular mortality and the propensity to take estrogen (and presumably other medications).4 Similarly, aspirin users may have already been at lower risk of colon cancer because of early-life socioeconomic conditions or other unmeasured confounders. Chan et al ask us to disregard randomized controlled trials showing no benefit of aspirin because of differences in doses and treatment length. It is, however, the results of observational studies that should be accepted only with great caution. Their best use, with respect to therapeutics, is to identify interventions worthy of a randomized trial.

Financial Disclosures: None reported.

References
Chan A, Giovannucci E, Meyerhardt JA.  et al.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.  JAMA. 2005;294914-923
PubMed
Grodstein F, Stampfer M, Colditz G.  et al.  Postmenopausal hormone therapy and mortality.  N Engl J Med. 1997;3361769-1775
PubMed
Rossouw JE, Anderson GL, Prentice RL.  et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;288321-333
PubMed
Lawlor D, Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials.  Am J Public Health. 2004;942149-2154
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Chan A, Giovannucci E, Meyerhardt JA.  et al.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.  JAMA. 2005;294914-923
PubMed
Grodstein F, Stampfer M, Colditz G.  et al.  Postmenopausal hormone therapy and mortality.  N Engl J Med. 1997;3361769-1775
PubMed
Rossouw JE, Anderson GL, Prentice RL.  et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;288321-333
PubMed
Lawlor D, Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials.  Am J Public Health. 2004;942149-2154
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.